Highly Novel Drugs Outperformed Less Novel Drugs In Gross And Net Revenues In The US, Driven Primarily By Utilization, 2013–19
Health Affairs · 01.08.2026 · 45 (8) · 846-854
DOI: 10.1377/hlthaff.2026.00054 ↗Kurz gefasst
Fachartikel in der Zeitschrift Health Affairs, erschienen am 01.08.2026. Verfasst von Boshen Jiao und 2 weiteren Autor:innen. Beteiligte Einrichtung: Boshen Jiao, University of Southern California, Los Angeles, California. Hauptthemen laut MEDLINE: Prescription Drugs, Drug Costs, Drug Industry, Drug Utilization. Die Arbeit nennt 29 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Boshen Jiao, University of Southern California, Los Angeles, California.
- Ian S. Haworth, University of Southern California.
- Darius N. Lakdawalla (dlakdawa@usc.edu), University of Southern California.
Zitieren
APA
Jiao, B., Haworth, I. S., & Lakdawalla, D. N. (2026). Highly Novel Drugs Outperformed Less Novel Drugs In Gross And Net Revenues In The US, Driven Primarily By Utilization, 2013–19. Health Affairs, 45(8), 846-854. https://doi.org/10.1377/hlthaff.2026.00054
Vancouver
Jiao B, Haworth IS, Lakdawalla DN. Highly Novel Drugs Outperformed Less Novel Drugs In Gross And Net Revenues In The US, Driven Primarily By Utilization, 2013–19. Health Affairs. 2026;45(8):846-854. doi:10.1377/hlthaff.2026.00054
BibTeX
@article{Jiao2026,
author = {Jiao, Boshen and Haworth, Ian S and Lakdawalla, Darius N},
title = {Highly Novel Drugs Outperformed Less Novel Drugs In Gross And Net Revenues In The US, Driven Primarily By Utilization, 2013–19},
journal = {Health Affairs},
year = {2026},
volume = {45},
number = {8},
pages = {846--854},
doi = {10.1377/hlthaff.2026.00054}
}
EUVIMED